More stories

  • in

    ‘The Last of Us’ Season 2, Episode 5 Recap: Once Upon a Time

    Dina fills in some blanks about her past. Ellie finds the first of her intended targets.‘The Last of Us’ Season 2, Episode 5Early in this week’s episode of “The Last of Us,” Dina tells Ellie a story about what her life was like when she was 8 years old, surviving the apocalypse in a cabin in a sparsely populated forest north of Santa Fe, N.M. One day back then, Dina grabbed a gun and went for a walk, without permission. When she returned, she found a raider in their house and her mother and sister dead.She killed the intruder — the first person she ever killed. Ever since, Dina has wondered what would have happened if she had been home when the raider arrived. Would she have been forced to watch him beat her family to death?There are different conclusions we could draw from all this. On the one hand, Dina suggests her experience helps her empathize with Ellie’s decision to hunt down Abby. Dina knows that if she had not killed her family’s murderer right away, she would have tracked him down until the job was done.But was her in-the-moment act of vengeance “justice,” exactly? Or just survival? Dina says that even if her family had hurt the raider’s family first, they would not have deserved to die the way they did; and she says that Joel did not deserve to be brutally slain, no matter what he did. Dina never proposes this directly — and would maybe disagree strongly with I am about to say — but the logical endpoint of her argument is that no one “deserves” to be killed. The act of taking a life should be a necessity, not a notion.Dina concludes her monologue by giving Ellie a choice, to press on or head home. Interestingly, Dina insists that there is “no right answer,” which is subtly different from “no wrong answer.” (It’s as if she were saying that all of their choices are equally cursed.) Anyway, Ellie sees only one option, so the mission continues.This week’s episode is ripe with bad vibes. For one thing, this is now the third week in a row that we have spent in Seattle, and after the variety of locations and stories that helped distinguish “The Last of Us” Season 1 from other end-times TV dramas, a certain exhausting repetitiveness is starting to set in here. The story feels a bit stuck.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe. More

  • in

    Just About Everything That’s Changed Since Congestion Pricing Took Effect

    <!–> [–><!–> –><!–> [–><!–> –><!–> [–><!–>Almost immediately after the tolls went into effect Jan. 5 — charging most vehicles $9 to enter Manhattan from 60th Street south to the Battery — they began to alter traffic patterns, commuter behavior, transit service, even the sound of gridlock and the on-time arrival of school buses.–><!–> –><!–> [!–> […] More

  • in

    Trump Plan Would Tie Some Drug Prices to What Peer Nations Pay

    The president announced an executive order aimed at lowering U.S. drug costs, revisiting an idea that was blocked in court during his first term.President Trump will sign an executive order on Monday aimed at lowering some drug prices in the United States by aligning them with what other wealthy countries pay, he said on Truth Social on Sunday evening.The proposal he described, which alone cannot shift federal policy, is what he calls a “most favored nation” pricing model. Mr. Trump did not provide details about which type of insurance the plan would apply to or how many drugs it would target, but he indicated that the United States should pay the lowest price among its peer countries.“Our Country will finally be treated fairly, and our citizens Healthcare Costs will be reduced by numbers never even thought of before,” he wrote in his social media post.Any such plan will most likely be subject to challenges in court, and it is not clear whether it will pass legal muster, especially without action by Congress.In his first term, Mr. Trump tried unsuccessfully to enact a version of this idea for Medicare, the health insurance program that covers 68 million Americans who are over 65 or have disabilities. That plan would have applied only to 50 drugs, administered at clinics and hospitals, that are paid for by Medicare. A federal court blocked it, ruling that the administration had skipped steps in the policymaking process.The pharmaceutical industry bitterly opposes the idea, which would almost certainly cut into its profits, and has been lobbying against it as discussions of the policy have regained steam in Washington in recent weeks. Companies have warned that such a policy would lead them to spend less on research, depriving patients of new medicines.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe. More

  • in

    Why Patients Are Being Forced to Switch to a 2nd-Choice Obesity Drug

    CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed by insurance that disrupt treatments for patients.Tens of thousands of Americans will soon be forced by their health insurance to switch from one popular obesity drug to another that produces less weight loss.It is the latest example of the consequences of secret deals between drugmakers and middlemen, known as pharmacy benefit managers, that are hired by employers to oversee prescription coverage for Americans. Employers pay lower drug prices but their workers are blocked from getting competing treatments, a type of insurance denial that has grown much more common in the past decade.One of the largest benefit managers, CVS Health’s Caremark, made the decision to exclude Zepbound in spite of research that found that it resulted in more weight loss than Wegovy, which will continue to be covered.Those research findings, first announced in December, were confirmed in an article published on Sunday in The New England Journal of Medicine. The study involved a large clinical trial comparing the drugs that was funded by Eli Lilly, the maker of Zepbound. Earlier research not financed by Eli Lilly reached similar conclusions.Ellen Davis, 63, of Huntington, Mass., is one of the patients affected by Caremark’s decision. “It feels like the rug is getting pulled out from under my feet,” she said.After taking Zepbound for a year, she has lost 85 pounds and her health has improved, she said. She retired after working for 34 years at Verizon, which hired Caremark for her drug coverage.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe. More

  • in

    Fear of Sleep

    On This Week’s Episode:The comedian Mike Birbiglia got used to strange things happening to him when he slept — until something happened that almost killed him. “This American Life” brings you this and other reasons to fear sleep, including bedbugs, “The Shining” and mild-mannered husbands who turn into maniacs while asleep.Mike Birbiglia in his film “Sleepwalk With Me.”IFC FilmsNew York Times Audio is home to the “This American Life” archive. Download the app — available to Times news subscribers on iOS — and sign up for our weekly newsletter. More

  • in

    Rodrigo Duterte Is Expected to Again Become Mayor of Davao City

    Former President Rodrigo Duterte, who faces international court charges of crimes against humanity, remains very popular at home.Six weeks ago, a van piled high with flowers pulled up at the International Criminal Court’s detention center in The Hague. The court also received deliveries of birthday cards. Lots and lots of them.They were all for the newest inmate, Rodrigo Duterte, the former president of the Philippines, who turned 80 on March 28. He is accused of crimes against humanity, and he could spend the rest of his life in prison.“The place was inundated with flowers, and I brought some of the mail out because they didn’t know what to do with it,” Nicholas Kaufman, Mr. Duterte’s lawyer, said in a telephone interview. He said he had left with three sacks of mail for Mr. Duterte that the court was unable to vet. In the Philippines, thousands of people dressed in the green associated with Mr. Duterte’s political party flooded the streets of Davao City.Mr. Duterte, who ordered a brutal antidrug campaign in which tens of thousands of people died during his presidency, remains very popular in the Philippines. With Filipinos voting in midterm elections on Monday, he is expected to win another term as mayor of Davao City, his eighth, by a landslide. For now, he remains eligible for office.Mr. Duterte’s sudden arrest and extradition to The Hague in March has sharply divided the Philippines. While some polls show that a majority of Filipinos back the international investigation, many of Mr. Duterte’s supporters believe that he is a victim of political persecution by President Ferdinand Marcos Jr., once an ally of the Duterte clan.Soon after Mr. Duterte’s dramatic arrest, Mr. Marcos’s approval rating plummeted to 25 percent from 42 percent a month earlier, in a survey conducted by Pulse Asia. But that of Sara Duterte — the current vice president and daughter of Mr. Duterte — rose to 59 percent from 52 percent.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe. More

  • in

    ‘Viva Papa Leo!’ At U.S. Masses, Dawn of Homegrown Pope Brings an Air of Electricity.

    The Rev. Gosbert Rwezahura opened Mass on Sunday morning by saying what everyone in the pews was thinking. “Habemus papam!” he exclaimed at Christ Our Savior Parish in South Holland, Ill. Beaming, he added, “He is one of our own!”It was the first Sunday in American history with an American pope seated on the throne of St. Peter in Rome. At parishes across the country, Catholics filed into the pews with a sense of wonder, hope and pride over Pope Leo XIV.At Christ Our Savior, the pride was personal: Today’s parish was formed from others in the area around the South Side of Chicago that includes a now-closed church where the pope attended as a child.Father Rwezahura put it simply: “We are the home parish of the pope!”“I’m so full and so proud, I don’t know what to do,” said Janice I. Sims, 75. “I’m definitely blessed because I lived long enough to see it happen.” Others there traded anecdotes about brushes with the future pope, back when he was known as Robert Prevost: the music director who played at a wedding he officiated, the deacon who went to high school where his mother was the school librarian.At the standing-room-only 10:30 a.m. Mass at Holy Name Cathedral in Chicago, the Rev. Ton Nguyen began his homily by exclaiming “Viva Papa Leo the 14th!” The congregation applauded. Outside the church, yellow and white bunting hung in celebration.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe. More

  • in

    NYT Crossword Answers for May 12, 2025

    Boy, oh, boy: Christina Iverson’s latest crossword is a fun one.Jump to: Today’s Theme | Tricky CluesMONDAY PUZZLE — Solving a crossword constructed by a New York Times puzzle editor is a funny exercise in restraint. You have to pretend as though the puzzle’s constructor — Christina Iverson, in this case — isn’t just steps away from you and available (theoretically) to answer questions about her puzzle.Even without her help, though, I found this puzzle to be eminently doable. It’s a beginner-friendly grid with lots of ways in. I didn’t know either of the 15-letter spanners at 17A and 59A, but I managed to crack them, using crossings and a little deductive reasoning.Today’s ThemeIn her constructor notes for the puzzle, Ms. Iverson said that today’s theme came to her while playing a game with her kids, who are 4 and 7. I’d say it shows: The joke is pretty silly, but it’s also adorable.When clicked on, themed entries are highlighted in yellow for digital solvers, so they’re relatively easy to spot. The first, at 17A, is a [Dessert cocktail with crème de cacao] — that’s a BRANDY ALEXANDER (news to me). At 34A, the [Classic board game with the Peppermint Forest and Lollipop Lane] is CANDY LAND. And the [Move from an acrobat or breakdancer] at 42A is a HANDSTAND.These entries certainly have a rhyming quality to them. What ties them all together, however, is a [Boy’s name … or how you might describe 17-, 34-, 42- or 59-Across?]: ANDY. These entries are AND-Y because AND appears multiple times in each one. If I could, I’d be shaking my head in dismay and nodding with delight at the same time.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.Thank you for your patience while we verify access.Already a subscriber? Log in.Want all of The Times? Subscribe. More